Frontiers in Oncology-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2211471, encodeId=cf8622114e198, content=偏重的研究方向：肿瘤;临床 经验分享：两个人审稿人都endorse了，编辑决定了一个月还没有消息🤪，到底是咋回事儿啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=613c5613981, createdName=ms9000000002911795, createdTime=Mon Jun 24 17:39:22 CST 2024, time=2024-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2212366, encodeId=e0e02212366f3, content=Editorial Assignment一个月了，还没分配编辑，有一样情况的么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c8d9273618, createdName=ms8000000484417572, createdTime=Sat Jun 29 17:33:15 CST 2024, time=2024-06-29, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2212618, encodeId=ab9b2212618b5, content=求教：一共送了2个外审，一个rejected，一个大修，现在到了 Interactive Review环节，给发了rejected notice，限我1周回复，仔细一看大修的外审显示revoked，只有编辑显示active，这种还有希望吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKcZDpJe6MqBsOtgBUOqlJPmiaWChJwP0vfBOPzVJKAjp6qWkO3AkXU25ficibbCiaI9fCQqsoFiaOvLkw/132, createdBy=66992508745, createdName=jm7009, createdTime=Mon Jul 01 15:51:13 CST 2024, time=2024-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2165771, encodeId=1b102165e71cf, content=审稿速度:3.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤 经验分享：非常水……😌😌😌😌, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ace2342720, createdName=小鹏友, createdTime=Mon Oct 30 18:20:01 CST 2023, time=2023-10-30, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=1052409, encodeId=26df105240933, content=审稿速度:2.0 | 投稿命中率:75.0 | 版面费用:2950.0 偏重的研究方向：肿瘤 经验分享：来还愿了 修回3天后审稿人全部endorse 第4天就直接accept了 从投稿到接收差不多两个月左右，这个速度简直感激, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=317, replyNumber=74, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fb605173656, createdName=146e0980m70暂无昵称, createdTime=Fri Sep 17 20:59:04 CST 2021, time=2021-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2129118, encodeId=7b09212911888, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;生信 经验分享：还是比较好投的，2月多投的，4月多就接受了；祝大家好运！ 11 Apr 2023 Article accepted for publication. 07 Apr 2023 Review of Review Editor 3 finalized. 01 Apr 2023 Review of Review Editor 4 finalized. 30 Mar 2023 Review of Review Editor 1 finalized. 17 Mar 2023 Interactive review forum activated. 07 Feb 2023 submitted manuscript, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b966155723, createdName=ms1000001631708013, createdTime=Fri Apr 28 21:51:41 CST 2023, time=2023-04-28, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2211104, encodeId=9106221110458, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;肿瘤免疫治疗;实体瘤 经验分享：2023年度影响因子为4.0分，还是不错的，每年稿件量如此之大，仍然能维持4分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Sat Jun 22 05:52:57 CST 2024, time=2024-06-22, status=1, ipAttribution=威斯康星), GetPortalCommentsPageByObjectIdResponse(id=2201986, encodeId=04b1220198613, content=这个投稿快一个月了，还一直在编辑手中，怎么办啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKcZDpJe6MqBsOtgBUOqlJPmiaWChJwP0vfBOPzVJKAjp6qWkO3AkXU25ficibbCiaI9fCQqsoFiaOvLkw/132, createdBy=66992508745, createdName=jm7009, createdTime=Mon May 06 11:46:16 CST 2024, time=2024-05-06, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2208898, encodeId=09ea220889850, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;非小细胞肺癌 经验分享：Received date: 22 Mar 2024 Editorial assignment start date: 25 Mar 2024 Independent review start date: 09 Apr 2024 Review finalized date: 27 May 2024 Final validation date: 06 Jun 2024 2个半月，建议推荐审稿人。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221102/369591c85731477baa49cc9e4607aa59/710024ddb86e4cc79b2f2a73449bbb88.jpg, createdBy=041e5339211, createdName=胸外科小大夫, createdTime=Sat Jun 08 04:34:14 CST 2024, time=2024-06-08, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=1214041, encodeId=a90f12140419a, content=editors assiment阶段就in review？？什么情况, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=32c32236172, createdName=12133f96m16(暂无昵称), createdTime=Mon Apr 25 08:49:30 CST 2022, time=2022-04-25, status=1, ipAttribution=)]

2024-06-24 ms9000000002911795

偏重的研究方向：肿瘤;临床
经验分享：两个人审稿人都endorse了，编辑决定了一个月还没有消息🤪，到底是咋回事儿啊

3 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2211471, encodeId=cf8622114e198, content=偏重的研究方向：肿瘤;临床 经验分享：两个人审稿人都endorse了，编辑决定了一个月还没有消息🤪，到底是咋回事儿啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=613c5613981, createdName=ms9000000002911795, createdTime=Mon Jun 24 17:39:22 CST 2024, time=2024-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2212366, encodeId=e0e02212366f3, content=Editorial Assignment一个月了，还没分配编辑，有一样情况的么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c8d9273618, createdName=ms8000000484417572, createdTime=Sat Jun 29 17:33:15 CST 2024, time=2024-06-29, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2212618, encodeId=ab9b2212618b5, content=求教：一共送了2个外审，一个rejected，一个大修，现在到了 Interactive Review环节，给发了rejected notice，限我1周回复，仔细一看大修的外审显示revoked，只有编辑显示active，这种还有希望吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKcZDpJe6MqBsOtgBUOqlJPmiaWChJwP0vfBOPzVJKAjp6qWkO3AkXU25ficibbCiaI9fCQqsoFiaOvLkw/132, createdBy=66992508745, createdName=jm7009, createdTime=Mon Jul 01 15:51:13 CST 2024, time=2024-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2165771, encodeId=1b102165e71cf, content=审稿速度:3.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤 经验分享：非常水……😌😌😌😌, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ace2342720, createdName=小鹏友, createdTime=Mon Oct 30 18:20:01 CST 2023, time=2023-10-30, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=1052409, encodeId=26df105240933, content=审稿速度:2.0 | 投稿命中率:75.0 | 版面费用:2950.0 偏重的研究方向：肿瘤 经验分享：来还愿了 修回3天后审稿人全部endorse 第4天就直接accept了 从投稿到接收差不多两个月左右，这个速度简直感激, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=317, replyNumber=74, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fb605173656, createdName=146e0980m70暂无昵称, createdTime=Fri Sep 17 20:59:04 CST 2021, time=2021-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2129118, encodeId=7b09212911888, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;生信 经验分享：还是比较好投的，2月多投的，4月多就接受了；祝大家好运！ 11 Apr 2023 Article accepted for publication. 07 Apr 2023 Review of Review Editor 3 finalized. 01 Apr 2023 Review of Review Editor 4 finalized. 30 Mar 2023 Review of Review Editor 1 finalized. 17 Mar 2023 Interactive review forum activated. 07 Feb 2023 submitted manuscript, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b966155723, createdName=ms1000001631708013, createdTime=Fri Apr 28 21:51:41 CST 2023, time=2023-04-28, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2211104, encodeId=9106221110458, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;肿瘤免疫治疗;实体瘤 经验分享：2023年度影响因子为4.0分，还是不错的，每年稿件量如此之大，仍然能维持4分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Sat Jun 22 05:52:57 CST 2024, time=2024-06-22, status=1, ipAttribution=威斯康星), GetPortalCommentsPageByObjectIdResponse(id=2201986, encodeId=04b1220198613, content=这个投稿快一个月了，还一直在编辑手中，怎么办啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKcZDpJe6MqBsOtgBUOqlJPmiaWChJwP0vfBOPzVJKAjp6qWkO3AkXU25ficibbCiaI9fCQqsoFiaOvLkw/132, createdBy=66992508745, createdName=jm7009, createdTime=Mon May 06 11:46:16 CST 2024, time=2024-05-06, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2208898, encodeId=09ea220889850, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;非小细胞肺癌 经验分享：Received date: 22 Mar 2024 Editorial assignment start date: 25 Mar 2024 Independent review start date: 09 Apr 2024 Review finalized date: 27 May 2024 Final validation date: 06 Jun 2024 2个半月，建议推荐审稿人。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221102/369591c85731477baa49cc9e4607aa59/710024ddb86e4cc79b2f2a73449bbb88.jpg, createdBy=041e5339211, createdName=胸外科小大夫, createdTime=Sat Jun 08 04:34:14 CST 2024, time=2024-06-08, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=1214041, encodeId=a90f12140419a, content=editors assiment阶段就in review？？什么情况, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=32c32236172, createdName=12133f96m16(暂无昵称), createdTime=Mon Apr 25 08:49:30 CST 2022, time=2022-04-25, status=1, ipAttribution=)]

2024-06-29 ms8000000484417572 来自浙江省

Editorial Assignment一个月了，还没分配编辑，有一样情况的么？

4 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2211471, encodeId=cf8622114e198, content=偏重的研究方向：肿瘤;临床 经验分享：两个人审稿人都endorse了，编辑决定了一个月还没有消息🤪，到底是咋回事儿啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=613c5613981, createdName=ms9000000002911795, createdTime=Mon Jun 24 17:39:22 CST 2024, time=2024-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2212366, encodeId=e0e02212366f3, content=Editorial Assignment一个月了，还没分配编辑，有一样情况的么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c8d9273618, createdName=ms8000000484417572, createdTime=Sat Jun 29 17:33:15 CST 2024, time=2024-06-29, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2212618, encodeId=ab9b2212618b5, content=求教：一共送了2个外审，一个rejected，一个大修，现在到了 Interactive Review环节，给发了rejected notice，限我1周回复，仔细一看大修的外审显示revoked，只有编辑显示active，这种还有希望吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKcZDpJe6MqBsOtgBUOqlJPmiaWChJwP0vfBOPzVJKAjp6qWkO3AkXU25ficibbCiaI9fCQqsoFiaOvLkw/132, createdBy=66992508745, createdName=jm7009, createdTime=Mon Jul 01 15:51:13 CST 2024, time=2024-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2165771, encodeId=1b102165e71cf, content=审稿速度:3.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤 经验分享：非常水……😌😌😌😌, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ace2342720, createdName=小鹏友, createdTime=Mon Oct 30 18:20:01 CST 2023, time=2023-10-30, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=1052409, encodeId=26df105240933, content=审稿速度:2.0 | 投稿命中率:75.0 | 版面费用:2950.0 偏重的研究方向：肿瘤 经验分享：来还愿了 修回3天后审稿人全部endorse 第4天就直接accept了 从投稿到接收差不多两个月左右，这个速度简直感激, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=317, replyNumber=74, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fb605173656, createdName=146e0980m70暂无昵称, createdTime=Fri Sep 17 20:59:04 CST 2021, time=2021-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2129118, encodeId=7b09212911888, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;生信 经验分享：还是比较好投的，2月多投的，4月多就接受了；祝大家好运！ 11 Apr 2023 Article accepted for publication. 07 Apr 2023 Review of Review Editor 3 finalized. 01 Apr 2023 Review of Review Editor 4 finalized. 30 Mar 2023 Review of Review Editor 1 finalized. 17 Mar 2023 Interactive review forum activated. 07 Feb 2023 submitted manuscript, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b966155723, createdName=ms1000001631708013, createdTime=Fri Apr 28 21:51:41 CST 2023, time=2023-04-28, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2211104, encodeId=9106221110458, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;肿瘤免疫治疗;实体瘤 经验分享：2023年度影响因子为4.0分，还是不错的，每年稿件量如此之大，仍然能维持4分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Sat Jun 22 05:52:57 CST 2024, time=2024-06-22, status=1, ipAttribution=威斯康星), GetPortalCommentsPageByObjectIdResponse(id=2201986, encodeId=04b1220198613, content=这个投稿快一个月了，还一直在编辑手中，怎么办啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKcZDpJe6MqBsOtgBUOqlJPmiaWChJwP0vfBOPzVJKAjp6qWkO3AkXU25ficibbCiaI9fCQqsoFiaOvLkw/132, createdBy=66992508745, createdName=jm7009, createdTime=Mon May 06 11:46:16 CST 2024, time=2024-05-06, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2208898, encodeId=09ea220889850, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;非小细胞肺癌 经验分享：Received date: 22 Mar 2024 Editorial assignment start date: 25 Mar 2024 Independent review start date: 09 Apr 2024 Review finalized date: 27 May 2024 Final validation date: 06 Jun 2024 2个半月，建议推荐审稿人。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221102/369591c85731477baa49cc9e4607aa59/710024ddb86e4cc79b2f2a73449bbb88.jpg, createdBy=041e5339211, createdName=胸外科小大夫, createdTime=Sat Jun 08 04:34:14 CST 2024, time=2024-06-08, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=1214041, encodeId=a90f12140419a, content=editors assiment阶段就in review？？什么情况, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=32c32236172, createdName=12133f96m16(暂无昵称), createdTime=Mon Apr 25 08:49:30 CST 2022, time=2022-04-25, status=1, ipAttribution=)]

2024-07-01 jm7009

求教：一共送了2个外审，一个rejected，一个大修，现在到了 Interactive Review环节，给发了rejected notice，限我1周回复，仔细一看大修的外审显示revoked，只有编辑显示active，这种还有希望吗

2 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2211471, encodeId=cf8622114e198, content=偏重的研究方向：肿瘤;临床 经验分享：两个人审稿人都endorse了，编辑决定了一个月还没有消息🤪，到底是咋回事儿啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=613c5613981, createdName=ms9000000002911795, createdTime=Mon Jun 24 17:39:22 CST 2024, time=2024-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2212366, encodeId=e0e02212366f3, content=Editorial Assignment一个月了，还没分配编辑，有一样情况的么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c8d9273618, createdName=ms8000000484417572, createdTime=Sat Jun 29 17:33:15 CST 2024, time=2024-06-29, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2212618, encodeId=ab9b2212618b5, content=求教：一共送了2个外审，一个rejected，一个大修，现在到了 Interactive Review环节，给发了rejected notice，限我1周回复，仔细一看大修的外审显示revoked，只有编辑显示active，这种还有希望吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKcZDpJe6MqBsOtgBUOqlJPmiaWChJwP0vfBOPzVJKAjp6qWkO3AkXU25ficibbCiaI9fCQqsoFiaOvLkw/132, createdBy=66992508745, createdName=jm7009, createdTime=Mon Jul 01 15:51:13 CST 2024, time=2024-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2165771, encodeId=1b102165e71cf, content=审稿速度:3.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤 经验分享：非常水……😌😌😌😌, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ace2342720, createdName=小鹏友, createdTime=Mon Oct 30 18:20:01 CST 2023, time=2023-10-30, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=1052409, encodeId=26df105240933, content=审稿速度:2.0 | 投稿命中率:75.0 | 版面费用:2950.0 偏重的研究方向：肿瘤 经验分享：来还愿了 修回3天后审稿人全部endorse 第4天就直接accept了 从投稿到接收差不多两个月左右，这个速度简直感激, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=317, replyNumber=74, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fb605173656, createdName=146e0980m70暂无昵称, createdTime=Fri Sep 17 20:59:04 CST 2021, time=2021-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2129118, encodeId=7b09212911888, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;生信 经验分享：还是比较好投的，2月多投的，4月多就接受了；祝大家好运！ 11 Apr 2023 Article accepted for publication. 07 Apr 2023 Review of Review Editor 3 finalized. 01 Apr 2023 Review of Review Editor 4 finalized. 30 Mar 2023 Review of Review Editor 1 finalized. 17 Mar 2023 Interactive review forum activated. 07 Feb 2023 submitted manuscript, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b966155723, createdName=ms1000001631708013, createdTime=Fri Apr 28 21:51:41 CST 2023, time=2023-04-28, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2211104, encodeId=9106221110458, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;肿瘤免疫治疗;实体瘤 经验分享：2023年度影响因子为4.0分，还是不错的，每年稿件量如此之大，仍然能维持4分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Sat Jun 22 05:52:57 CST 2024, time=2024-06-22, status=1, ipAttribution=威斯康星), GetPortalCommentsPageByObjectIdResponse(id=2201986, encodeId=04b1220198613, content=这个投稿快一个月了，还一直在编辑手中，怎么办啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKcZDpJe6MqBsOtgBUOqlJPmiaWChJwP0vfBOPzVJKAjp6qWkO3AkXU25ficibbCiaI9fCQqsoFiaOvLkw/132, createdBy=66992508745, createdName=jm7009, createdTime=Mon May 06 11:46:16 CST 2024, time=2024-05-06, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2208898, encodeId=09ea220889850, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;非小细胞肺癌 经验分享：Received date: 22 Mar 2024 Editorial assignment start date: 25 Mar 2024 Independent review start date: 09 Apr 2024 Review finalized date: 27 May 2024 Final validation date: 06 Jun 2024 2个半月，建议推荐审稿人。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221102/369591c85731477baa49cc9e4607aa59/710024ddb86e4cc79b2f2a73449bbb88.jpg, createdBy=041e5339211, createdName=胸外科小大夫, createdTime=Sat Jun 08 04:34:14 CST 2024, time=2024-06-08, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=1214041, encodeId=a90f12140419a, content=editors assiment阶段就in review？？什么情况, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=32c32236172, createdName=12133f96m16(暂无昵称), createdTime=Mon Apr 25 08:49:30 CST 2022, time=2022-04-25, status=1, ipAttribution=)]

2023-10-30 小鹏友来自重庆

审稿速度:3.0 | 投稿命中率:95.0
偏重的研究方向：肿瘤
经验分享：非常水……😌😌😌😌

70 8

展开8条回复

[GetPortalCommentsPageByObjectIdResponse(id=2211471, encodeId=cf8622114e198, content=偏重的研究方向：肿瘤;临床 经验分享：两个人审稿人都endorse了，编辑决定了一个月还没有消息🤪，到底是咋回事儿啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=613c5613981, createdName=ms9000000002911795, createdTime=Mon Jun 24 17:39:22 CST 2024, time=2024-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2212366, encodeId=e0e02212366f3, content=Editorial Assignment一个月了，还没分配编辑，有一样情况的么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c8d9273618, createdName=ms8000000484417572, createdTime=Sat Jun 29 17:33:15 CST 2024, time=2024-06-29, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2212618, encodeId=ab9b2212618b5, content=求教：一共送了2个外审，一个rejected，一个大修，现在到了 Interactive Review环节，给发了rejected notice，限我1周回复，仔细一看大修的外审显示revoked，只有编辑显示active，这种还有希望吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKcZDpJe6MqBsOtgBUOqlJPmiaWChJwP0vfBOPzVJKAjp6qWkO3AkXU25ficibbCiaI9fCQqsoFiaOvLkw/132, createdBy=66992508745, createdName=jm7009, createdTime=Mon Jul 01 15:51:13 CST 2024, time=2024-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2165771, encodeId=1b102165e71cf, content=审稿速度:3.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤 经验分享：非常水……😌😌😌😌, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ace2342720, createdName=小鹏友, createdTime=Mon Oct 30 18:20:01 CST 2023, time=2023-10-30, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=1052409, encodeId=26df105240933, content=审稿速度:2.0 | 投稿命中率:75.0 | 版面费用:2950.0 偏重的研究方向：肿瘤 经验分享：来还愿了 修回3天后审稿人全部endorse 第4天就直接accept了 从投稿到接收差不多两个月左右，这个速度简直感激, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=317, replyNumber=74, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fb605173656, createdName=146e0980m70暂无昵称, createdTime=Fri Sep 17 20:59:04 CST 2021, time=2021-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2129118, encodeId=7b09212911888, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;生信 经验分享：还是比较好投的，2月多投的，4月多就接受了；祝大家好运！ 11 Apr 2023 Article accepted for publication. 07 Apr 2023 Review of Review Editor 3 finalized. 01 Apr 2023 Review of Review Editor 4 finalized. 30 Mar 2023 Review of Review Editor 1 finalized. 17 Mar 2023 Interactive review forum activated. 07 Feb 2023 submitted manuscript, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b966155723, createdName=ms1000001631708013, createdTime=Fri Apr 28 21:51:41 CST 2023, time=2023-04-28, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2211104, encodeId=9106221110458, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;肿瘤免疫治疗;实体瘤 经验分享：2023年度影响因子为4.0分，还是不错的，每年稿件量如此之大，仍然能维持4分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Sat Jun 22 05:52:57 CST 2024, time=2024-06-22, status=1, ipAttribution=威斯康星), GetPortalCommentsPageByObjectIdResponse(id=2201986, encodeId=04b1220198613, content=这个投稿快一个月了，还一直在编辑手中，怎么办啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKcZDpJe6MqBsOtgBUOqlJPmiaWChJwP0vfBOPzVJKAjp6qWkO3AkXU25ficibbCiaI9fCQqsoFiaOvLkw/132, createdBy=66992508745, createdName=jm7009, createdTime=Mon May 06 11:46:16 CST 2024, time=2024-05-06, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2208898, encodeId=09ea220889850, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;非小细胞肺癌 经验分享：Received date: 22 Mar 2024 Editorial assignment start date: 25 Mar 2024 Independent review start date: 09 Apr 2024 Review finalized date: 27 May 2024 Final validation date: 06 Jun 2024 2个半月，建议推荐审稿人。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221102/369591c85731477baa49cc9e4607aa59/710024ddb86e4cc79b2f2a73449bbb88.jpg, createdBy=041e5339211, createdName=胸外科小大夫, createdTime=Sat Jun 08 04:34:14 CST 2024, time=2024-06-08, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=1214041, encodeId=a90f12140419a, content=editors assiment阶段就in review？？什么情况, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=32c32236172, createdName=12133f96m16(暂无昵称), createdTime=Mon Apr 25 08:49:30 CST 2022, time=2022-04-25, status=1, ipAttribution=)]

2021-09-17 146e0980m70暂无昵称

审稿速度:2.0 | 投稿命中率:75.0 | 版面费用:2950.0
偏重的研究方向：肿瘤
经验分享：来还愿了
修回3天后审稿人全部endorse
第4天就直接accept了
从投稿到接收差不多两个月左右，这个速度简直感激

317 74

展开74条回复

[GetPortalCommentsPageByObjectIdResponse(id=2211471, encodeId=cf8622114e198, content=偏重的研究方向：肿瘤;临床 经验分享：两个人审稿人都endorse了，编辑决定了一个月还没有消息🤪，到底是咋回事儿啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=613c5613981, createdName=ms9000000002911795, createdTime=Mon Jun 24 17:39:22 CST 2024, time=2024-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2212366, encodeId=e0e02212366f3, content=Editorial Assignment一个月了，还没分配编辑，有一样情况的么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c8d9273618, createdName=ms8000000484417572, createdTime=Sat Jun 29 17:33:15 CST 2024, time=2024-06-29, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2212618, encodeId=ab9b2212618b5, content=求教：一共送了2个外审，一个rejected，一个大修，现在到了 Interactive Review环节，给发了rejected notice，限我1周回复，仔细一看大修的外审显示revoked，只有编辑显示active，这种还有希望吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKcZDpJe6MqBsOtgBUOqlJPmiaWChJwP0vfBOPzVJKAjp6qWkO3AkXU25ficibbCiaI9fCQqsoFiaOvLkw/132, createdBy=66992508745, createdName=jm7009, createdTime=Mon Jul 01 15:51:13 CST 2024, time=2024-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2165771, encodeId=1b102165e71cf, content=审稿速度:3.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤 经验分享：非常水……😌😌😌😌, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ace2342720, createdName=小鹏友, createdTime=Mon Oct 30 18:20:01 CST 2023, time=2023-10-30, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=1052409, encodeId=26df105240933, content=审稿速度:2.0 | 投稿命中率:75.0 | 版面费用:2950.0 偏重的研究方向：肿瘤 经验分享：来还愿了 修回3天后审稿人全部endorse 第4天就直接accept了 从投稿到接收差不多两个月左右，这个速度简直感激, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=317, replyNumber=74, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fb605173656, createdName=146e0980m70暂无昵称, createdTime=Fri Sep 17 20:59:04 CST 2021, time=2021-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2129118, encodeId=7b09212911888, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;生信 经验分享：还是比较好投的，2月多投的，4月多就接受了；祝大家好运！ 11 Apr 2023 Article accepted for publication. 07 Apr 2023 Review of Review Editor 3 finalized. 01 Apr 2023 Review of Review Editor 4 finalized. 30 Mar 2023 Review of Review Editor 1 finalized. 17 Mar 2023 Interactive review forum activated. 07 Feb 2023 submitted manuscript, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b966155723, createdName=ms1000001631708013, createdTime=Fri Apr 28 21:51:41 CST 2023, time=2023-04-28, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2211104, encodeId=9106221110458, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;肿瘤免疫治疗;实体瘤 经验分享：2023年度影响因子为4.0分，还是不错的，每年稿件量如此之大，仍然能维持4分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Sat Jun 22 05:52:57 CST 2024, time=2024-06-22, status=1, ipAttribution=威斯康星), GetPortalCommentsPageByObjectIdResponse(id=2201986, encodeId=04b1220198613, content=这个投稿快一个月了，还一直在编辑手中，怎么办啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKcZDpJe6MqBsOtgBUOqlJPmiaWChJwP0vfBOPzVJKAjp6qWkO3AkXU25ficibbCiaI9fCQqsoFiaOvLkw/132, createdBy=66992508745, createdName=jm7009, createdTime=Mon May 06 11:46:16 CST 2024, time=2024-05-06, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2208898, encodeId=09ea220889850, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;非小细胞肺癌 经验分享：Received date: 22 Mar 2024 Editorial assignment start date: 25 Mar 2024 Independent review start date: 09 Apr 2024 Review finalized date: 27 May 2024 Final validation date: 06 Jun 2024 2个半月，建议推荐审稿人。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221102/369591c85731477baa49cc9e4607aa59/710024ddb86e4cc79b2f2a73449bbb88.jpg, createdBy=041e5339211, createdName=胸外科小大夫, createdTime=Sat Jun 08 04:34:14 CST 2024, time=2024-06-08, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=1214041, encodeId=a90f12140419a, content=editors assiment阶段就in review？？什么情况, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=32c32236172, createdName=12133f96m16(暂无昵称), createdTime=Mon Apr 25 08:49:30 CST 2022, time=2022-04-25, status=1, ipAttribution=)]

2023-04-28 ms1000001631708013 来自浙江省

审稿速度:2.0 | 投稿命中率:75.0
偏重的研究方向：肿瘤;生信
经验分享：还是比较好投的，2月多投的，4月多就接受了；祝大家好运！
11 Apr 2023 Article accepted for publication.
07 Apr 2023 Review of Review Editor 3 finalized.
01 Apr 2023 Review of Review Editor 4 finalized.
30 Mar 2023 Review of Review Editor 1 finalized.
17 Mar 2023 Interactive review forum activated.
07 Feb 2023 submitted manuscript

124 9

展开9条回复

[GetPortalCommentsPageByObjectIdResponse(id=2211471, encodeId=cf8622114e198, content=偏重的研究方向：肿瘤;临床 经验分享：两个人审稿人都endorse了，编辑决定了一个月还没有消息🤪，到底是咋回事儿啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=613c5613981, createdName=ms9000000002911795, createdTime=Mon Jun 24 17:39:22 CST 2024, time=2024-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2212366, encodeId=e0e02212366f3, content=Editorial Assignment一个月了，还没分配编辑，有一样情况的么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c8d9273618, createdName=ms8000000484417572, createdTime=Sat Jun 29 17:33:15 CST 2024, time=2024-06-29, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2212618, encodeId=ab9b2212618b5, content=求教：一共送了2个外审，一个rejected，一个大修，现在到了 Interactive Review环节，给发了rejected notice，限我1周回复，仔细一看大修的外审显示revoked，只有编辑显示active，这种还有希望吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKcZDpJe6MqBsOtgBUOqlJPmiaWChJwP0vfBOPzVJKAjp6qWkO3AkXU25ficibbCiaI9fCQqsoFiaOvLkw/132, createdBy=66992508745, createdName=jm7009, createdTime=Mon Jul 01 15:51:13 CST 2024, time=2024-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2165771, encodeId=1b102165e71cf, content=审稿速度:3.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤 经验分享：非常水……😌😌😌😌, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ace2342720, createdName=小鹏友, createdTime=Mon Oct 30 18:20:01 CST 2023, time=2023-10-30, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=1052409, encodeId=26df105240933, content=审稿速度:2.0 | 投稿命中率:75.0 | 版面费用:2950.0 偏重的研究方向：肿瘤 经验分享：来还愿了 修回3天后审稿人全部endorse 第4天就直接accept了 从投稿到接收差不多两个月左右，这个速度简直感激, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=317, replyNumber=74, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fb605173656, createdName=146e0980m70暂无昵称, createdTime=Fri Sep 17 20:59:04 CST 2021, time=2021-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2129118, encodeId=7b09212911888, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;生信 经验分享：还是比较好投的，2月多投的，4月多就接受了；祝大家好运！ 11 Apr 2023 Article accepted for publication. 07 Apr 2023 Review of Review Editor 3 finalized. 01 Apr 2023 Review of Review Editor 4 finalized. 30 Mar 2023 Review of Review Editor 1 finalized. 17 Mar 2023 Interactive review forum activated. 07 Feb 2023 submitted manuscript, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b966155723, createdName=ms1000001631708013, createdTime=Fri Apr 28 21:51:41 CST 2023, time=2023-04-28, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2211104, encodeId=9106221110458, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;肿瘤免疫治疗;实体瘤 经验分享：2023年度影响因子为4.0分，还是不错的，每年稿件量如此之大，仍然能维持4分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Sat Jun 22 05:52:57 CST 2024, time=2024-06-22, status=1, ipAttribution=威斯康星), GetPortalCommentsPageByObjectIdResponse(id=2201986, encodeId=04b1220198613, content=这个投稿快一个月了，还一直在编辑手中，怎么办啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKcZDpJe6MqBsOtgBUOqlJPmiaWChJwP0vfBOPzVJKAjp6qWkO3AkXU25ficibbCiaI9fCQqsoFiaOvLkw/132, createdBy=66992508745, createdName=jm7009, createdTime=Mon May 06 11:46:16 CST 2024, time=2024-05-06, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2208898, encodeId=09ea220889850, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;非小细胞肺癌 经验分享：Received date: 22 Mar 2024 Editorial assignment start date: 25 Mar 2024 Independent review start date: 09 Apr 2024 Review finalized date: 27 May 2024 Final validation date: 06 Jun 2024 2个半月，建议推荐审稿人。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221102/369591c85731477baa49cc9e4607aa59/710024ddb86e4cc79b2f2a73449bbb88.jpg, createdBy=041e5339211, createdName=胸外科小大夫, createdTime=Sat Jun 08 04:34:14 CST 2024, time=2024-06-08, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=1214041, encodeId=a90f12140419a, content=editors assiment阶段就in review？？什么情况, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=32c32236172, createdName=12133f96m16(暂无昵称), createdTime=Mon Apr 25 08:49:30 CST 2022, time=2022-04-25, status=1, ipAttribution=)]

2024-06-22 侠胆医心来自威斯康星

审稿速度:3.0 | 投稿命中率:75.0
偏重的研究方向：肿瘤;肿瘤免疫治疗;实体瘤
经验分享：2023年度影响因子为4.0分，还是不错的，每年稿件量如此之大，仍然能维持4分

0 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2211471, encodeId=cf8622114e198, content=偏重的研究方向：肿瘤;临床 经验分享：两个人审稿人都endorse了，编辑决定了一个月还没有消息🤪，到底是咋回事儿啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=613c5613981, createdName=ms9000000002911795, createdTime=Mon Jun 24 17:39:22 CST 2024, time=2024-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2212366, encodeId=e0e02212366f3, content=Editorial Assignment一个月了，还没分配编辑，有一样情况的么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c8d9273618, createdName=ms8000000484417572, createdTime=Sat Jun 29 17:33:15 CST 2024, time=2024-06-29, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2212618, encodeId=ab9b2212618b5, content=求教：一共送了2个外审，一个rejected，一个大修，现在到了 Interactive Review环节，给发了rejected notice，限我1周回复，仔细一看大修的外审显示revoked，只有编辑显示active，这种还有希望吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKcZDpJe6MqBsOtgBUOqlJPmiaWChJwP0vfBOPzVJKAjp6qWkO3AkXU25ficibbCiaI9fCQqsoFiaOvLkw/132, createdBy=66992508745, createdName=jm7009, createdTime=Mon Jul 01 15:51:13 CST 2024, time=2024-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2165771, encodeId=1b102165e71cf, content=审稿速度:3.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤 经验分享：非常水……😌😌😌😌, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ace2342720, createdName=小鹏友, createdTime=Mon Oct 30 18:20:01 CST 2023, time=2023-10-30, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=1052409, encodeId=26df105240933, content=审稿速度:2.0 | 投稿命中率:75.0 | 版面费用:2950.0 偏重的研究方向：肿瘤 经验分享：来还愿了 修回3天后审稿人全部endorse 第4天就直接accept了 从投稿到接收差不多两个月左右，这个速度简直感激, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=317, replyNumber=74, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fb605173656, createdName=146e0980m70暂无昵称, createdTime=Fri Sep 17 20:59:04 CST 2021, time=2021-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2129118, encodeId=7b09212911888, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;生信 经验分享：还是比较好投的，2月多投的，4月多就接受了；祝大家好运！ 11 Apr 2023 Article accepted for publication. 07 Apr 2023 Review of Review Editor 3 finalized. 01 Apr 2023 Review of Review Editor 4 finalized. 30 Mar 2023 Review of Review Editor 1 finalized. 17 Mar 2023 Interactive review forum activated. 07 Feb 2023 submitted manuscript, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b966155723, createdName=ms1000001631708013, createdTime=Fri Apr 28 21:51:41 CST 2023, time=2023-04-28, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2211104, encodeId=9106221110458, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;肿瘤免疫治疗;实体瘤 经验分享：2023年度影响因子为4.0分，还是不错的，每年稿件量如此之大，仍然能维持4分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Sat Jun 22 05:52:57 CST 2024, time=2024-06-22, status=1, ipAttribution=威斯康星), GetPortalCommentsPageByObjectIdResponse(id=2201986, encodeId=04b1220198613, content=这个投稿快一个月了，还一直在编辑手中，怎么办啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKcZDpJe6MqBsOtgBUOqlJPmiaWChJwP0vfBOPzVJKAjp6qWkO3AkXU25ficibbCiaI9fCQqsoFiaOvLkw/132, createdBy=66992508745, createdName=jm7009, createdTime=Mon May 06 11:46:16 CST 2024, time=2024-05-06, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2208898, encodeId=09ea220889850, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;非小细胞肺癌 经验分享：Received date: 22 Mar 2024 Editorial assignment start date: 25 Mar 2024 Independent review start date: 09 Apr 2024 Review finalized date: 27 May 2024 Final validation date: 06 Jun 2024 2个半月，建议推荐审稿人。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221102/369591c85731477baa49cc9e4607aa59/710024ddb86e4cc79b2f2a73449bbb88.jpg, createdBy=041e5339211, createdName=胸外科小大夫, createdTime=Sat Jun 08 04:34:14 CST 2024, time=2024-06-08, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=1214041, encodeId=a90f12140419a, content=editors assiment阶段就in review？？什么情况, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=32c32236172, createdName=12133f96m16(暂无昵称), createdTime=Mon Apr 25 08:49:30 CST 2022, time=2022-04-25, status=1, ipAttribution=)]

2024-05-06 jm7009 来自河南省

这个投稿快一个月了，还一直在编辑手中，怎么办啊

31 7

展开7条回复

[GetPortalCommentsPageByObjectIdResponse(id=2211471, encodeId=cf8622114e198, content=偏重的研究方向：肿瘤;临床 经验分享：两个人审稿人都endorse了，编辑决定了一个月还没有消息🤪，到底是咋回事儿啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=613c5613981, createdName=ms9000000002911795, createdTime=Mon Jun 24 17:39:22 CST 2024, time=2024-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2212366, encodeId=e0e02212366f3, content=Editorial Assignment一个月了，还没分配编辑，有一样情况的么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c8d9273618, createdName=ms8000000484417572, createdTime=Sat Jun 29 17:33:15 CST 2024, time=2024-06-29, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2212618, encodeId=ab9b2212618b5, content=求教：一共送了2个外审，一个rejected，一个大修，现在到了 Interactive Review环节，给发了rejected notice，限我1周回复，仔细一看大修的外审显示revoked，只有编辑显示active，这种还有希望吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKcZDpJe6MqBsOtgBUOqlJPmiaWChJwP0vfBOPzVJKAjp6qWkO3AkXU25ficibbCiaI9fCQqsoFiaOvLkw/132, createdBy=66992508745, createdName=jm7009, createdTime=Mon Jul 01 15:51:13 CST 2024, time=2024-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2165771, encodeId=1b102165e71cf, content=审稿速度:3.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤 经验分享：非常水……😌😌😌😌, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ace2342720, createdName=小鹏友, createdTime=Mon Oct 30 18:20:01 CST 2023, time=2023-10-30, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=1052409, encodeId=26df105240933, content=审稿速度:2.0 | 投稿命中率:75.0 | 版面费用:2950.0 偏重的研究方向：肿瘤 经验分享：来还愿了 修回3天后审稿人全部endorse 第4天就直接accept了 从投稿到接收差不多两个月左右，这个速度简直感激, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=317, replyNumber=74, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fb605173656, createdName=146e0980m70暂无昵称, createdTime=Fri Sep 17 20:59:04 CST 2021, time=2021-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2129118, encodeId=7b09212911888, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;生信 经验分享：还是比较好投的，2月多投的，4月多就接受了；祝大家好运！ 11 Apr 2023 Article accepted for publication. 07 Apr 2023 Review of Review Editor 3 finalized. 01 Apr 2023 Review of Review Editor 4 finalized. 30 Mar 2023 Review of Review Editor 1 finalized. 17 Mar 2023 Interactive review forum activated. 07 Feb 2023 submitted manuscript, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b966155723, createdName=ms1000001631708013, createdTime=Fri Apr 28 21:51:41 CST 2023, time=2023-04-28, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2211104, encodeId=9106221110458, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;肿瘤免疫治疗;实体瘤 经验分享：2023年度影响因子为4.0分，还是不错的，每年稿件量如此之大，仍然能维持4分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Sat Jun 22 05:52:57 CST 2024, time=2024-06-22, status=1, ipAttribution=威斯康星), GetPortalCommentsPageByObjectIdResponse(id=2201986, encodeId=04b1220198613, content=这个投稿快一个月了，还一直在编辑手中，怎么办啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKcZDpJe6MqBsOtgBUOqlJPmiaWChJwP0vfBOPzVJKAjp6qWkO3AkXU25ficibbCiaI9fCQqsoFiaOvLkw/132, createdBy=66992508745, createdName=jm7009, createdTime=Mon May 06 11:46:16 CST 2024, time=2024-05-06, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2208898, encodeId=09ea220889850, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;非小细胞肺癌 经验分享：Received date: 22 Mar 2024 Editorial assignment start date: 25 Mar 2024 Independent review start date: 09 Apr 2024 Review finalized date: 27 May 2024 Final validation date: 06 Jun 2024 2个半月，建议推荐审稿人。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221102/369591c85731477baa49cc9e4607aa59/710024ddb86e4cc79b2f2a73449bbb88.jpg, createdBy=041e5339211, createdName=胸外科小大夫, createdTime=Sat Jun 08 04:34:14 CST 2024, time=2024-06-08, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=1214041, encodeId=a90f12140419a, content=editors assiment阶段就in review？？什么情况, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=32c32236172, createdName=12133f96m16(暂无昵称), createdTime=Mon Apr 25 08:49:30 CST 2022, time=2022-04-25, status=1, ipAttribution=)]

2024-06-08 胸外科小大夫来自辽宁省

审稿速度:1.0 | 投稿命中率:50.0
偏重的研究方向：肿瘤;非小细胞肺癌
经验分享：Received date: 22 Mar 2024 Editorial assignment start date: 25 Mar 2024 Independent review start date: 09 Apr 2024 Review finalized date: 27 May 2024 Final validation date: 06 Jun 2024 2个半月，建议推荐审稿人。

11 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2211471, encodeId=cf8622114e198, content=偏重的研究方向：肿瘤;临床 经验分享：两个人审稿人都endorse了，编辑决定了一个月还没有消息🤪，到底是咋回事儿啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=613c5613981, createdName=ms9000000002911795, createdTime=Mon Jun 24 17:39:22 CST 2024, time=2024-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2212366, encodeId=e0e02212366f3, content=Editorial Assignment一个月了，还没分配编辑，有一样情况的么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c8d9273618, createdName=ms8000000484417572, createdTime=Sat Jun 29 17:33:15 CST 2024, time=2024-06-29, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2212618, encodeId=ab9b2212618b5, content=求教：一共送了2个外审，一个rejected，一个大修，现在到了 Interactive Review环节，给发了rejected notice，限我1周回复，仔细一看大修的外审显示revoked，只有编辑显示active，这种还有希望吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKcZDpJe6MqBsOtgBUOqlJPmiaWChJwP0vfBOPzVJKAjp6qWkO3AkXU25ficibbCiaI9fCQqsoFiaOvLkw/132, createdBy=66992508745, createdName=jm7009, createdTime=Mon Jul 01 15:51:13 CST 2024, time=2024-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2165771, encodeId=1b102165e71cf, content=审稿速度:3.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤 经验分享：非常水……😌😌😌😌, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ace2342720, createdName=小鹏友, createdTime=Mon Oct 30 18:20:01 CST 2023, time=2023-10-30, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=1052409, encodeId=26df105240933, content=审稿速度:2.0 | 投稿命中率:75.0 | 版面费用:2950.0 偏重的研究方向：肿瘤 经验分享：来还愿了 修回3天后审稿人全部endorse 第4天就直接accept了 从投稿到接收差不多两个月左右，这个速度简直感激, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=317, replyNumber=74, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fb605173656, createdName=146e0980m70暂无昵称, createdTime=Fri Sep 17 20:59:04 CST 2021, time=2021-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2129118, encodeId=7b09212911888, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;生信 经验分享：还是比较好投的，2月多投的，4月多就接受了；祝大家好运！ 11 Apr 2023 Article accepted for publication. 07 Apr 2023 Review of Review Editor 3 finalized. 01 Apr 2023 Review of Review Editor 4 finalized. 30 Mar 2023 Review of Review Editor 1 finalized. 17 Mar 2023 Interactive review forum activated. 07 Feb 2023 submitted manuscript, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b966155723, createdName=ms1000001631708013, createdTime=Fri Apr 28 21:51:41 CST 2023, time=2023-04-28, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2211104, encodeId=9106221110458, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;肿瘤免疫治疗;实体瘤 经验分享：2023年度影响因子为4.0分，还是不错的，每年稿件量如此之大，仍然能维持4分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Sat Jun 22 05:52:57 CST 2024, time=2024-06-22, status=1, ipAttribution=威斯康星), GetPortalCommentsPageByObjectIdResponse(id=2201986, encodeId=04b1220198613, content=这个投稿快一个月了，还一直在编辑手中，怎么办啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKcZDpJe6MqBsOtgBUOqlJPmiaWChJwP0vfBOPzVJKAjp6qWkO3AkXU25ficibbCiaI9fCQqsoFiaOvLkw/132, createdBy=66992508745, createdName=jm7009, createdTime=Mon May 06 11:46:16 CST 2024, time=2024-05-06, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2208898, encodeId=09ea220889850, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;非小细胞肺癌 经验分享：Received date: 22 Mar 2024 Editorial assignment start date: 25 Mar 2024 Independent review start date: 09 Apr 2024 Review finalized date: 27 May 2024 Final validation date: 06 Jun 2024 2个半月，建议推荐审稿人。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221102/369591c85731477baa49cc9e4607aa59/710024ddb86e4cc79b2f2a73449bbb88.jpg, createdBy=041e5339211, createdName=胸外科小大夫, createdTime=Sat Jun 08 04:34:14 CST 2024, time=2024-06-08, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=1214041, encodeId=a90f12140419a, content=editors assiment阶段就in review？？什么情况, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=32c32236172, createdName=12133f96m16(暂无昵称), createdTime=Mon Apr 25 08:49:30 CST 2022, time=2022-04-25, status=1, ipAttribution=)]

2022-04-25 12133f96m16(暂无昵称)

editors assiment阶段就in review？？什么情况

26 8

展开8条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务